Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors

被引:26
|
作者
Lu, Yipin [1 ]
Knapp, Mark [1 ]
Crawford, Kenneth [2 ]
Warne, Robert [2 ]
Elling, Robert [1 ]
Yan, Kelly [2 ]
Doyle, Michael [2 ]
Pardee, Gwynn [2 ]
Zhang, Li [2 ]
Ma, Sylvia [2 ]
Mamo, Mulugeta [1 ]
Ornelas, Elizabeth [1 ]
Pan, Yue [1 ]
Bussiere, Dirksen [1 ]
Jansen, Johanna [1 ]
Zaror, Isabel [2 ]
Lai, Albert [2 ]
Barsanti, Paul [1 ]
Sim, Janet [2 ]
机构
[1] Novartis Inst Biomed Res, Global Discovery Chem, Emeryville, CA 94608 USA
[2] Novartis Inst Biomed Res, Oncol, Emeryville, CA 94608 USA
关键词
ATR; PI3K alpha; mutant; crystal structure; ATR inhibitor; PROTEIN-KINASE-A; CELL-CYCLE; CANCER-CELLS; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; DISCOVERY; POTENT; THERAPY; IDENTIFICATION; DETERMINANTS;
D O I
10.1016/j.jmb.2017.04.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ATR, a protein kinase in the PIKK family, plays a critical role in the cell DNA-damage response and is an attractive anticancer drug target. Several potent and selective inhibitors of ATR have been reported showing significant antitumor efficacy, with most advanced ones entering clinical trials. However, due to the absence of an experimental ATR structure, the determinants contributing to ATR inhibitors' potency and specificity are not well understood. Here we present the mutations in the ATP-binding site of PI3K alpha to progressively transform the pocket to mimic that of ATR. The generated PI3K alpha mutants exhibit significantly improved affinity for selective ATR inhibitors in multiple chemical classes. Furthermore, we obtained the X-ray structures of the PI3K alpha mutants in complex with the ATR inhibitors. The crystal structures together with the analysis on the inhibitor affinity profile elucidate the roles of individual amino acid residues in the binding of ATR inhibitors, offering key insights for the binding mechanism and revealing the structure features important for the specificity of ATR inhibitors. The ability to obtain structural and binding data for these PI3K alpha mutants, together with their ATR-like inhibitor binding profiles, makes these chimeric PI3K alpha proteins valuable model systems for structure-based inhibitor design. (C) 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecomnnons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1684 / 1704
页数:21
相关论文
共 43 条
  • [1] Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels
    Dan, Shingo
    Sugita, Hironobu
    Yamazaki, Kanami
    Yamori, Takao
    CANCER RESEARCH, 2009, 69
  • [2] Methylation of NRIP3 Is a Synthetic Lethal Marker for Combined PI3K and ATR/ATM Inhibitors in Colorectal Cancer
    Zhang, Meiying
    Li, Xiaoyun
    Herman, James G.
    Gao, Aiai
    Wang, Qian
    Yao, Yuanxin
    Shen, Fangfang
    He, Kunlun
    Guo, Mingzhou
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (03)
  • [3] The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
    Sartori, Giulio
    Tarantelli, Chiara
    Spriano, Filippo
    Gaudio, Eugenio
    Cascione, Luciano
    Mascia, Michele
    Barreca, Marilia
    Arribas, Alberto J.
    Licenziato, Luca
    Golino, Gaetanina
    Ferragamo, Adele
    Pileri, Stefano
    Damia, Giovanna
    Zucca, Emanuele
    Stathis, Anastasios
    Politz, Oliver
    Wengner, Antje M.
    Bertoni, Francesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (01) : 191 - 205
  • [4] Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors
    Muranen, Taru
    Meric-Bernstam, Funda
    Mills, Gordon B.
    CANCER CELL, 2014, 26 (01) : 7 - 9
  • [5] Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors
    Al Hasan, Mohammad
    Sabirianov, Matthew
    Redwine, Grace
    Goettsch, Kaitlin
    Yang, Stephen X.
    Zhong, Haizhen A.
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2023, 121
  • [6] TR-FRET binding assays for PI3K family inhibitors
    Hereley, Sara B.
    Wolken, Jill K.
    Frazee, William J.
    Eliason, Hildegard C.
    Riddle, Steven M.
    CANCER RESEARCH, 2010, 70
  • [7] Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity
    Gong, Grace Q.
    Kendall, Jackie D.
    Dickson, James M. J.
    Rewcastle, Gordon W.
    Buchanan, Christina M.
    Denny, William A.
    Shepherd, Peter R.
    Flanagan, Jack U.
    BIOCHEMICAL JOURNAL, 2017, 474 : 2261 - 2276
  • [8] Quantitative structure-selectivity relationship (QSSR)-based molecular insight into the cross-reactivity and specificity of chemotherapeutic inhibitors between PI3K and PI3K
    Ding, Xi
    Liu, Xingcai
    Zhu, Lixia
    JOURNAL OF CHEMOMETRICS, 2017, 31 (12)
  • [9] Water Molecules Increases Binding Affinity of Natural PI3Kγ Inhibitors Against Cancer
    Sharma, Pooja
    Shukla, Aparna
    Kalani, Komal
    Dubey, Vijaya
    Srivastava, Santosh Kumar
    Luqman, Suaib
    Khan, Feroz
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2015, 11 (04) : 304 - 320
  • [10] Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma
    Oh, Danielle H.
    Ma, Xiao
    Hogg, Simon J.
    He, Jackson
    Kearney, Conor
    Brasacchio, Daniella
    Susanto, Olivia
    Maher, Belinda
    Jennings, Ian G.
    Newbold, Andrea
    Fraser, Peter
    Gruber, Emily
    Kats, Lev M.
    Gregory, Gareth P.
    Johnstone, Ricky W.
    Thompson, Philip E.
    Shortt, Jake
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (36)